central nervous system diseases

Summary

Summary: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.

Top Publications

  1. Mayer M, Breithaupt C, Reindl M, Schanda K, Rostasy K, Berger T, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol. 2013;191:3594-604 pubmed publisher
    ..The majority of human anti-MOG Abs did not recognize rodent MOG, which has implications for animal studies. Our findings might assist in future detection of potential mimotopes and pave the way to Ag-specific depletion. ..
  2. Alexander J, Prouty L, Tsunoda I, Ganta C, Minagar A. Venous endothelial injury in central nervous system diseases. BMC Med. 2013;11:219 pubmed publisher
  3. Jin X, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33:601-13 pubmed publisher
  4. Zivadinov R, Chung C. Potential involvement of the extracranial venous system in central nervous system disorders and aging. BMC Med. 2013;11:260 pubmed publisher
    ..The idea has been changing with regards to the extracranial venous system...
  5. Segal B. Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr Opin Neurol. 2013;26:307-13 pubmed publisher
    ..This review focuses on central nervous system (CNS) complications of sarcoidosis...
  6. London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44-53 pubmed publisher
    ..Translation of eye research to CNS disease, and deciphering the role of immune cells in these two systems, could improve our understanding and, potentially, the treatment of neurodegenerative disorders...
  7. Muldoon L, Alvarez J, Begley D, Boado R, del Zoppo G, Doolittle N, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. 2013;33:13-21 pubmed publisher
    ..This review article was developed from reports presented at the 2011 Annual Blood-Brain Barrier Consortium Meeting...
  8. Hautala T, Mähönen S, Sironen T, Hautala N, Paakko E, Karttunen A, et al. Central nervous system-related symptoms and findings are common in acute Puumala hantavirus infection. Ann Med. 2010;42:344-51 pubmed publisher
    ..Recent case reports and retrospective studies suggest that NE may damage the pituitary gland. Based on these observations, our goal was to explore the nature of this complication prospectively...
  9. Zhou J, Zhou S. Isorhynchophylline: A plant alkaloid with therapeutic potential for cardiovascular and central nervous system diseases. Fitoterapia. 2012;83:617-26 pubmed publisher
    ..It requires more in vivo validations and further investigations of antihypertensive and neuroprotective mechanisms of isorhynchophylline...

More Information

Publications62

  1. Gascon Bayarri J, Mana J, Martinez Yelamos S, Murillo O, Rene R, Rubio F. Neurosarcoidosis: report of 30 cases and a literature survey. Eur J Intern Med. 2011;22:e125-32 pubmed publisher
    ..Neurosarcoidosis accounts for approximately 5% of cases of sarcoidosis...
  2. Willey J, Elkind M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol. 2010;67:1062-7 pubmed publisher
  3. Zamboni P, Galeotti R. The chronic cerebrospinal venous insufficiency syndrome. Phlebology. 2010;25:269-79 pubmed publisher
    ..Restenosis rate was found out elevated in the IJVs, but negligible in the AZ. However, PTA seems to positively influence clinical and QoL parameters of the associated MS and warrants further randomized control trials...
  4. McKeon A, Tracy J, Pittock S, Parisi J, Klein C, Lennon V. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol. 2011;68:1282-9 pubmed publisher
    ..To investigate the full extent of Purkinje cell cytoplasmic autoantibody type 1 autoimmunity (classically associated with paraneoplastic cerebellar degeneration) from clinical, immunohistochemical, and neuropathological perspectives...
  5. Lochhead J, Thorne R. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614-28 pubmed publisher
    ..Finally we review both pre-clinical and clinical studies involving intranasal delivery of biologics to the CNS...
  6. Banister S, Kassiou M. The therapeutic potential of sigma (?) receptors for the treatment of central nervous system diseases: evaluation of the evidence. Curr Pharm Des. 2012;18:884-901 pubmed
    ..This review will assess the validity of receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials...
  7. Mouridsen S, Rich B, Isager T. A longitudinal study of epilepsy and other central nervous system diseases in individuals with and without a history of infantile autism. Brain Dev. 2011;33:361-6 pubmed publisher
    ..To compare the prevalence and types of epilepsy and other central nervous system (CNS) diseases in a clinical sample of 118 individuals diagnosed as children with infantile autism (IA) with 336 matched controls from the general population...
  8. Schmitz G, Leuthäuser Jaschinski K, Orso E. Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?. Cent Nerv Syst Agents Med Chem. 2009;9:307-30 pubmed
    ..They are suitable biomarker targets for diagnosis and prognosis and maybe also therapy of central nervous system disease. ..
  9. McGonigle P. Peptide therapeutics for CNS indications. Biochem Pharmacol. 2012;83:559-66 pubmed publisher
  10. Rossi B, Angiari S, Zenaro E, Budui S, Constantin G. Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J Leukoc Biol. 2011;89:539-56 pubmed publisher
    ..These emerging roles for leukocytes and leukocyte adhesion mechanisms in CNS diseases provide insight into the mechanisms of brain damage and may contribute to the development of novel therapeutic strategies...
  11. Teissier N, Delezoide A, Mas A, Khung Savatovsky S, Bessières B, Nardelli J, et al. Inner ear lesions in congenital cytomegalovirus infection of human fetuses. Acta Neuropathol. 2011;122:763-74 pubmed publisher
    ..In addition, the occurrence of SNHL depends on the intensity and duration of the viral infection and inflammation...
  12. Ludyga T, Kazibudzki M, Simka M, Hartel M, Swierad M, Piegza J, et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?. Phlebology. 2010;25:286-95 pubmed publisher
    ..Although balloon angioplasty and stenting seem to be safe procedures, there are currently no data on the treatment of a large group of patients with this vascular pathology...
  13. Celebi A, Deveci S, Gursoy A, Kolukisa M. A case of isolated neurosarcoidosis associated with psychosis. Neurosciences (Riyadh). 2013;18:70-3 pubmed
    ..The patient was treated with corticosteroids and responded well to medical therapy. The diagnosis of isolated neurosarcoidosis is a challenge and may require histological examination...
  14. Borsook D, Becerra L, Fava M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry. 2013;3:e282 pubmed publisher
  15. Mandel J, Olar A, Aldape K, Tremont Lukats I. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344:229-31 pubmed publisher
  16. Sohn M, Culver D, Judson M, Scott T, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. 2014;347:195-8 pubmed publisher
    ..Spinal cord neurosarcoidosis (SN) is problematic to diagnose because it mimics other inflammatory neurologic diseases. The authors report the clinical features of 29 SN cases...
  17. Kral J, Ludvig N. Subarachnoid pharmacodialysis for central nervous system disorders. Med Hypotheses. 2013;80:105-11 pubmed publisher
  18. Lanzino D, Rabinstein A, Kinlaw D, Hepburn S, Ness B, Olson K, et al. Coordination tests in persons with acute central nervous system pathology: assessment of interrater reliability and known-group validity. J Neurol Phys Ther. 2012;36:122-30 pubmed publisher
    ..This study investigated the interrater reliability and known-group validity of limb coordination tests in participants with acute central nervous system (CNS) pathology...
  19. Van Hove I, Lemmens K, Van de Velde S, Verslegers M, Moons L. Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. J Neurochem. 2012;123:203-16 pubmed publisher
    ..Moreover, a strict spatiotemporal MMP-3 up-regulation in the injured or diseased CNS might support remyelination and neuroprotection, as well as genesis and migration of stem cells in the damaged brain...
  20. Psimaras D, Bompaire F, Taillia H, Ricard D, Taillibert S. [Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies]. Bull Cancer. 2012;99:851-63 pubmed publisher
  21. Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol. 2012;30:S73-5 pubmed
    ..Given this result, the anti-IL-6 receptor antibody tocilizumab was administered and a good improvement of inflammatory parameters and a satisfactory increase of the walking distance were achieved...
  22. Menninger A. [On Freud's contributions to Villaret's Handwörterbuch der Gesamten Medizin (1888-91)]. Luzif Amor. 2012;25:83-105 pubmed
    ..The section "II. physiology" of the article on the brain which has come to be ascribed to him is positively attributed to the physiologist Johannes Gad, the article on infantile paralysis to Alfred Goldscheider...
  23. Tayebati S, Nwankwo I, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des. 2013;19:510-26 pubmed
    ..This route offers attractive advantages, and pharmaceutical scientists and anatomists should collaborate to improve CNS drug compliance and to increase the number of compounds that can be administered intranasally. ..
  24. Carelli V, Sabatelli M, Carrozzo R, Rizza T, Schimpf S, Wissinger B, et al. 'Behr syndrome' with OPA1 compound heterozygote mutations. Brain. 2015;138:e321 pubmed publisher
  25. Melzer N, Meuth S, Wiendl H. Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol. 2013;260:1215-33 pubmed publisher
  26. Varcasia A, Pipia A, Arru D, Pes A, Tamponi C, Dore F, et al. Morphological and molecular characterization of bovine coenurosis in Sardinia, Italy. Parasitol Res. 2013;112:2079-82 pubmed publisher
    ..Morphological features of the cysts and mt-DNA sequencing confirm that the parasites were T. multiceps Coenuri...
  27. Aubourg P. Gene therapy for disorders of the central nervous system. Handb Clin Neurol. 2013;113:1859-66 pubmed publisher
  28. Trueman R, Klein A, Lindgren H, Lelos M, Dunnett S. Repair of the CNS using endogenous and transplanted neural stem cells. Curr Top Behav Neurosci. 2013;15:357-98 pubmed publisher
    ..Alongside exogenous cell therapy, the role of endogenous neurogenesis in each of the three diseases is outlined and methods to enhance this phenomenon are discussed...
  29. Louveau A, Plog B, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest. 2017;127:3210-3219 pubmed publisher
    ..Future studies should explore the communications between the glymphatic system and meningeal lymphatics in CNS disorders and develop new therapeutic modalities targeting these systems...
  30. Lin H, Otsu M, Nakauchi H. Stem cell therapy: an exercise in patience and prudence. Philos Trans R Soc Lond B Biol Sci. 2013;368:20110334 pubmed publisher
    ..This review shall focus on a discussion regarding the current status of stem cell therapy, the issues surrounding it and its future prospects with a general background on the regulatory networks underlying pluripotency...
  31. MacKenzie C, Haggett E, Pinchbeck G, Marr C. Ultrasonographic assessment of the atlanto-occipital space in healthy Thoroughbred foals and Thoroughbred foals with neonatal maladjustment syndrome. Vet J. 2017;223:55-59 pubmed publisher
    ..Several ultrasonographic measurements of the AO space were significantly different between healthy foals and foals with NMS. Further investigation is warranted to investigate the clinical application of this technique. ..
  32. Virarkar M, Alappat L, Bradford P, Awad A. L-arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit Rev Food Sci Nutr. 2013;53:1157-67 pubmed publisher
    ..This review summarizes current knowledge of the role of NO in the CNS and the role of diet in regulating the levels of NO. ..
  33. Gill A, Kolson D. Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol. 2013;33:307-59 pubmed
    ..Thus, DMF might protect against systemic and CNS complications in HIV infection through its effective suppression of immune activation, oxidative stress, HIV replication, and macrophage-associated neuronal injury. ..
  34. Borah A, Paul R, Choudhury S, Choudhury A, Bhuyan B, Das Talukdar A, et al. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. CNS Neurosci Ther. 2013;19:847-53 pubmed publisher
  35. Choi K. The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders. Expert Opin Drug Discov. 2013;8:919-31 pubmed publisher
    ..T-type channels in the CNS are involved in various neurophysiological and pathophysiological states, and thus have become a promising therapeutic target...
  36. Sofou K, Steneryd K, Wiklund L, Tulinius M, Darin N. MRI of the brain in childhood-onset mitochondrial disorders with central nervous system involvement. Mitochondrion. 2013;13:364-71 pubmed publisher
  37. Bai W, Xu W, Feng Y, Huang H, Li X, Deng C, et al. Fifty-Hertz electromagnetic fields facilitate the induction of rat bone mesenchymal stromal cells to differentiate into functional neurons. Cytotherapy. 2013;15:961-70 pubmed publisher
    ..In the present study, we explored the efficacy of EMF on the induction of rat BMSC differentiation into neurons in vitro...
  38. Cragg J, Warner F, Finnerup N, Jensen M, Mercier C, Richards J, et al. Meta-analysis of placebo responses in central neuropathic pain: impact of subject, study, and pain characteristics. Pain. 2016;157:530-40 pubmed publisher
    ..Further study is warranted to identify factors that may explain the impact of pain duration on the placebo response at the individual subject level. ..
  39. Ruha A, Levine M. Central nervous system toxicity. Emerg Med Clin North Am. 2014;32:205-21 pubmed publisher
    ..Toxicity may manifest as altered thought content resulting in psychosis or confusion; may affect arousal, resulting in lethargy, stupor, or coma; or may affect both elements of consciousness. Seizures may also occur...
  40. Robinson M, Holloway R. Palliative Care in Neurology. Mayo Clin Proc. 2017;92:1592-1601 pubmed publisher
  41. Floel A. tDCS-enhanced motor and cognitive function in neurological diseases. Neuroimage. 2014;85 Pt 3:934-47 pubmed publisher
    ..Its use in reducing disease-specific symptoms like dystonia or epileptic seizures is still unclear. ..
  42. Carda S, Cisari C, Invernizzi M. Sarcopenia or muscle modifications in neurologic diseases: a lexical or patophysiological difference?. Eur J Phys Rehabil Med. 2013;49:119-30 pubmed
    ..Since sarcopenia of the elderly and muscle modifications and muscle atrophy in CNS diseases have different mechanisms, it is probable that they do not respond equally to the same treatments...
  43. Fitzgerald M, Hodgetts S, Van Den Heuvel C, Natoli R, Hart N, Valter K, et al. Red/near-infrared irradiation therapy for treatment of central nervous system injuries and disorders. Rev Neurosci. 2013;24:205-26 pubmed publisher
  44. Fawcett J, Schwab M, Montani L, Brazda N, Müller H. Defeating inhibition of regeneration by scar and myelin components. Handb Clin Neurol. 2012;109:503-22 pubmed publisher
    ..Methods to counteract these forms of inhibition have been identified, and these treatments promote axon regeneration in the damaged spinal cord, and in some cases recovery of function through enhanced plasticity...
  45. Pesaresi I, Sabato M, Desideri I, Puglioli M, Moretti P, Cosottini M. 3.0T MR investigation of CLIPPERS: role of susceptibility weighted and perfusion weighted imaging. Magn Reson Imaging. 2013;31:1640-2 pubmed publisher
    ..Further observations are needed to evaluate if these findings are peculiar for CLIPPERS and if they might have a role in a non-invasive diagnosis of the disease...
  46. Dietrich J, Klein J. Imaging of cancer therapy-induced central nervous system toxicity. Neurol Clin. 2014;32:147-57 pubmed publisher
  47. Parker W, Orlova K, Parker W, Birnbaum J, Krymskaya V, Goncharov D, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013;5:182ra53 pubmed publisher
    ..Our findings demonstrate a mechanistic link between STRADA loss and mTORC1 hyperactivity in PMSE, and suggest that mTORC1 inhibition may be a potential treatment for PMSE as well as other mTOR-associated neurodevelopmental disorders...
  48. Tjora E, Wathle G, Erchinger F, Engjom T, Molven A, Aksnes L, et al. Exocrine pancreatic function in hepatocyte nuclear factor 1?-maturity-onset diabetes of the young (HNF1B-MODY) is only moderately reduced: compensatory hypersecretion from a hypoplastic pancreas. Diabet Med. 2013;30:946-55 pubmed publisher
    ..To examine the exocrine pancreatic function in carriers of the hepatocyte nuclear factor 1? gene (HNF1B) mutation by direct testing...
  49. Maki T, Hayakawa K, Pham L, Xing C, Lo E, Arai K. Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases. CNS Neurol Disord Drug Targets. 2013;12:302-15 pubmed
    ..Many central nervous system diseases, which lead to NVU dysfunction, have common features such as glial activation/transformation and ..
  50. Wu W, Tal A, Zhang K, Babb J, Ratai E, Gonzalez R, et al. Structure-specific glial response in a macaque model of neuroAIDS: multivoxel proton magnetic resonance spectroscopic imaging at 3 Tesla. AIDS. 2013;27:2519-28 pubmed publisher
  51. Basak S, Lu C, Basak A. Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases. Curr Med Chem. 2016;23:714-45 pubmed
    ..This manuscript provides a comprehensive review of these rare and unconventional types of protein modifications and their functional implications to health, metabolism and disease conditions. ..
  52. Bensamoun D, Gros A, Manera V, König A, Guerin O, Robert P, et al. [Neuropsychiatric disorders and technological solutions]. Soins Gerontol. 2016;21:18-20 pubmed publisher
    ..A personalised approach to patients can further enhance their adherence and involvement. ..
  53. Tsai J, Baker A. Influenza-associated neurological complications. Neurocrit Care. 2013;18:118-30 pubmed publisher
    ..Vigilance and awareness of these clinical entities are key in the neurologist and intensivist's role in surveillance and early recognition of pandemic influenza, and in ensuring improved survival for affected patients...